Related Experiment Video
Updated: Jan 24, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
Naiara Martínez-Vélez1,2,3, Marc Garcia-Moure1,2,3, Miguel Marigil1,2,3
1Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
Abstract:
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).
Insights
Delta-24-RGD oncolytic virotherapy shows promise for treating pediatric high-grade gliomas (pHGG) and diffuse intrinsic pontine gliomas (DIPGs). This adenovirus therapy is safe and enhances survival by directly attacking tumors and stimulating an immune response.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Pediatric high-grade gliomas (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive brain tumors with limited treatment options.
- Oncolytic virotherapy presents a promising therapeutic strategy for these challenging pediatric cancers.
Purpose of the Study:
- To evaluate the safety and efficacy of Delta-24-RGD, a replication-competent adenovirus, in preclinical models of pHGG and DIPGs.
- To investigate the mechanisms underlying the anti-glioma effects of Delta-24-RGD.
Main Methods:
- Administration of Delta-24-RGD to immunodeficient and immunocompetent mouse models of pHGG and DIPGs.
- Assessment of tumor growth, survival rates, and immune responses post-treatment.
Main Results:
- Delta-24-RGD demonstrated a safe profile in mice.
- Significant increases in survival were observed in both immunodeficient and immunocompetent models.
- The anti-glioma effect was attributed to both direct oncolysis and virus-induced immune responses.
Conclusions:
- Delta-24-RGD is a safe and effective oncolytic virus for pediatric high-grade gliomas and DIPGs.
- The dual mechanism of action (oncolysis and immune stimulation) supports its therapeutic potential.
- These findings have led to a Phase I/II clinical trial for newly diagnosed DIPG.
Related Concept Videos
The Delta-to-Delta Circuit
The Y-to-Delta Circuit
The initial step in analyzing a wye-to-delta circuit is to assume a positive phase sequence. These phase voltages are then utilized to calculate the line voltages that occur directly across the delta-connected load impedances. Van, Vbn, and Vcn are the phase voltages in wye, and Vab, Vbc, and Vca are the line voltages for a delta circuit. The relation between...
The Delta-to-Y Circuit
What are Viruses?
Holter Monitor: 24-Hour Monitoring
Pharmacokinetics in Pediatric Patients: Drug Excretion

